Direkt zum Inhalt
Merck

Effect of thiazide treatment on biliary lipid composition in healthy volunteers.

European journal of clinical pharmacology (1989-01-01)
B Angelin
ZUSAMMENFASSUNG

An increased incidence of cholecystitis has been observed in thiazide-treated patients. In order to test the possibility that the therapy might have caused an increase in the cholesterol saturation of gallbladder bile, biliary lipid composition was determined in fasting duodenal bile obtained from 10 healthy individuals after cholecystokinin injection, before and after 3 weeks of treatment with hydrochlorthiazide. The mean relative concentration of cholesterol was increased in 6 subjects, from 4.7 to 5.6 mol%, and the cholesterol saturation of bile was increased in 7, from 69 to 81%. These preliminary results indicate that thiazide treatment may to some extent increase biliary cholesterol saturation, and this may, at least in part, explain the higher prevalence of symptomatic gallbladder disease during such therapy.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Supelco
Hydrochlorthiazid, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Hydrochlorthiazid, crystalline
Supelco
Hydrochlorothiazide solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Hydrochlorthiazid, meets USP testing specifications